Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer

NCT00959946 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00959946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2009
Completion date
March 31, 2011
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer (parts 1 and 2), advanced cholangiocarcinoma (part 1), advanced colorectal cancer (part 1), advanced glioblastoma multiforme (part 1), advanced pancreatic cancer (part 1)